Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies
Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies
复制标题
DOI：
10.1016/j.ejca.2013.07.001
复制
发表时间：
2013-09-01
影响因子：
8.4
通讯作者：
Eggermont, Alexander M. M.
中科院分区：
文献类型：
--
作者：
Robert, Caroline;Soria, Jean-Charles;Eggermont, Alexander M. M.
2013年，程序性死亡-1受体(PD-1)/其配体(PD-L1)抗体改变了肿瘤学的格局。最成熟的结果是在晚期黑色素瘤患者身上获得的。它们表明重要的应答率和高质量的反应或持续时间较长。在肾癌和肺癌中也表现出了显着的活性。因此，很明显，这些抗体具有非常广泛的潜力，许多肿瘤类型的试验正在启动。打破肿瘤部位的耐受性是一个强有力的现象，与其他检查点抑制剂如ipilimumab的协同作用也在2013年得到了证明。长期的肿瘤控制现在似乎是可以实现的，因此通过调节免疫系统来实现临床治愈的概念正在出现。这些抗体使免疫治疗走到了前列，并表明免疫调节将成为今后治疗策略的关键组成部分。正因为如此，PD-1/PD-L1抗体被认为是“年度药物”。(C)2013爱思唯尔有限公司。保留所有权利。
Programmed death-1 receptor (PD-1)/its ligand (PD-L1) antibodies have changed the landscape in oncology in 2013. The most mature results have been obtained in advanced melanoma patients. They indicate important response rates and high quality responses or prolonged duration. Also in renal cancer and in lung cancer remarkable activity has been demonstrated. Thus it is clear that these antibodies have a very broad potential and trials in many tumour types are being initiated. Breaking tolerance at the tumour site is a potent phenomenon and the potential for synergy with other checkpoint inhibitors such as ipilimumab have also been demonstrated in 2013. Long term tumour control now seems achievable and thus the concept of a clinical cure is emerging by modulation of the immune system. These antibodies bring immunotherapy to the forefront and indicate that immune-modulation will be a key component of therapeutic strategies from now on. Because of all these reasons PD-1/PD-L1 antibodies are considered 'drug of the year'. (C) 2013 Elsevier Ltd. All rights reserved.